ArticleJournal of molecular histology2026
Potential regulation mechanism of lncRNA OIP5-AS1 influencing prognosis in acute myeloid leukemia patients via the miR-15a-5p/FOXO1 axis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with AML have a poor prognosis due to recurrence and high-risk genetic factors. lncRNA OIP5-AS1 exhibits differential expression among AML patients with varying genetic risks. The aim of this study is to examine the clinical value and regulation mechanisms of OIP5-AS1 in AML. RT-qPCR was used to evaluate the OIP5-AS1, miR-15a-5p, and FOXO1 levels in patients with AML and cells, as well as the mRNA levels of Bcl-2, Bax, and Caspase-3 in AML cell. The CCK-8 test was employed to measure cell proliferation. Apoptosis rates were detected by flow cytometry. DLR experiments validated the interaction between OIP5-AS1, miR-15a-5p, and FOXO1. Compared with the controls, AML patients exhibited notably elevated levels of OIP5-AS1 and FOXO1, along with markedly reduced miR-15a-5p expression. Furthermore, OIP5-AS1 levels effectively differentiate patients with AML from controls. Patients in the high OIP5-AS1 level group exhibited lower 5-year survival rates. Knockdown of OIP5-AS1 elevated miR-15a-5p levels, reduced cell proliferation capacity, and notably increased apoptosis. Furthermore, FOXO1, as a target gene of miR-15a-5p, showed a positive correlation with OIP5-AS1 level and a negative correlation with miR-15a-5p level. OIP5-AS1 exhibits significant diagnostic and prognostic value in AML, showing promise as a novel clinical biomarker. Knockdown of OIP5-AS1 leads to upregulation of miR-15a-5p level, thereby influencing proliferation and apoptosis processes in AML cells. This mechanism may provide a new therapeutic target for improving the prognosis of AML patients.
Indexed as
Identifiers
42599547What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.